公司财务与资本运作 - Ventripoint Diagnostics Ltd 宣布将通过发行普通股来支付可转换债券的利息 需获得多伦多证券交易所创业板批准 [1] - 公司将发行总计1,145,627股普通股 用于支付总计103,106.29美元的应付利息 这些利息涉及公司在2024年5月10日、6月28日、9月20日以及2025年1月17日、2月7日、3月21日发行的特定未偿还可转换债券 [1] - 可转换债券的年利率为10% 每6个月支付一次利息 此次用于支付利息的股票发行价格被认定为每股0.089美元 股票发行后将面临4个月零1天的限售期 此次发行不会导致公司产生控制权人 [1] 公司业务与技术 - Ventripoint 已成为将人工智能应用于超声心动图领域的行业领导者 [2] - 公司的VMS产品由其专有的基于知识的重建技术驱动 该技术是十年研发的成果 能提供与磁共振成像同等精确的心脏容积测量 这种经济实惠的黄金标准替代方案能让心脏病专家更自信地管理患者 [2] - 公司的VMS+产品用途广泛 可与获得美国、欧洲和加拿大监管市场批准的任何厂商的所有超声系统兼容 [2]

Key Takeaways HOLX said its Genius AI flagged 32% of false-negative mammograms and identified cancer hidden in dense tissue.Researchers reviewed 7,500 3D exams and found HOLX AI detected nearly 90% of cancers seen by radiologists.HOLX noted the study shows AI's potential to boost early detection and strengthen future breast imaging tools.Hologic, Inc. (HOLX) recently announced the latest clinical evidence showing the effectiveness of its Genius AI-based mammography screening technology in improving breast c ...

Key Takeaways Hologic's Genius AI Detection flagged roughly 32% of false-negative mammograms in the 7,500-exam study.HOLX's AI technology correctly spotted the location of breast cancer in one-third of initially missed cases.Hologic's AI tool demonstrated similar accuracy to radiologists reviewing difficult breast cancer cases.Hologic’s (HOLX) AI-powered mammography solutions are gaining clinical momentum. Amid ongoing radiologist shortages, the company’s 3DQuorum technology has shown potential to streamlin ...

Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities New delivery model for ReWalk will integrate in-patient training and rehabilitation to support clinical adoption in physical rehabilitation settings Over 7 million survivors of spinal cord injury (SCI) globally could potentially benefit from ReWalk, an estimated $1.75 billion total addressable market for Lifeward MARLBOROUGH, Mass., YOKNEAM ILLIT,  ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Avanos Medical, Inc. (AVNS) is a medical technology company focusing on delivering medical device solutions. The Zacks Consensus Estimate for its current year earnings has been revised 3.3% downward over the last 60 days.Archer-Daniels-Midland Company (ADM) is an agricultural commodities and ingredients company. The Zacks Consensus Estimate for its current year earnings has been revised 8.6% downward over the last 60 days.Bank OZK (OZ ...

REGENSBURG, Germany, Dec. 17, 2025 /PRNewswire/ -- numares Health ("numares"), the transformative metabolomics company pioneering multidimensional biomarker insights that deliver clinical pathways for optimal patient care, today announces the expansion of its global footprint into the ASEAN region having received regulatory approval in Malaysia and subsequently securing its first contract for the AXINON® LDLp Test System ("AXINON") with BioD Medica, who specialise in introducing medical devices and healthca ...

PresentationRobert SassoonWater Tower Research LLC Hello, everybody. I'm Robert Sassoon, healthcare analyst at Water Tower Research. I have the double pleasure of hosting Kirk Huntsman, CEO of Vivos Therapeutics; and Brad Amman, the company's CFO, for this fireside chat. Vivos is a revenue stage medical technology company focused on developing and commercializing a suite of innovative diagnostic and nonsurgical treatment methods for patients suffering from breathing and sleep issues arising from certain de ...

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical†or the "Company†), a leading medical technology company focused on developing, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the appointment of Eric Schiller as Chief Technology Officer, effective December 29, 2025. Eric joins KORU Medical with more than 25 years of leadership experience across research & development,. ...

CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting at the J.P. Morgan 2026 Healthcare conference on Wednesday, January 14th at 4:30-5:10 pm PT in San Francisco, CA. During the conference, Carlsmed Management will be hosting 1x1 investor meetings. About Carlsmed, Inc. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery soluti ...

Riverwater Partners, an investment management company, released its “Small Cap Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. The Small Cap Core Strategy reported solid results for the quarter but did not keep pace with the sharp rally, thus lagging the benchmark. The market’s preference for lower-quality companies persisted in the quarter and contributed significantly to the benchmark’s outperformance. On the other hand, the strategy remains focused on higher-quality compa ...